<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>26(11)</volume><submitter>Ahmed AA</submitter><pubmed_abstract>&lt;h4>Objective&lt;/h4>This study assessed the anticancer and antimetastatic impact of rivaroxaban-ciprofloxacin mixture and explored its molecular mechanism by examining its ability to target the epithelial-mesenchymal transition (EMT) pathway.&lt;h4>Methods&lt;/h4>Following incubation periods of 24 and 72 hours, HeLa and normal human fibroblast (NHF) cell lines were employed to investigate the anticancer and safety properties of rivaroxaban, ciprofloxacin, rivaroxaban-ciprofloxacin mixture, and carboplatin, with concentrations varying from 0.1 to 1000 µg/ml. The wound healing assay (WHA) of cervical cancer cells was employed to assess the anti-metastatic effects of the mixture at three time points: 0, 12, and 24 hours.. A combination index (CI) and selectivity toxicity index (SI) score were estimat</pubmed_abstract><journal>Asian Pacific journal of cancer prevention : APJCP</journal><pagination>4195-4207</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12948181</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Dual Repurposing Strategy: Rivaroxaban and Ciprofloxacin as a Synergistic Anticancer Therapy in Cervical Cancer: Insight into Inhibition of Metastasis via Targeting the EMT Pathway.</pubmed_title><pmcid>PMC12948181</pmcid><pubmed_authors>Ahmed AA</pubmed_authors></additional><is_claimable>false</is_claimable><name>Dual Repurposing Strategy: Rivaroxaban and Ciprofloxacin as a Synergistic Anticancer Therapy in Cervical Cancer: Insight into Inhibition of Metastasis via Targeting the EMT Pathway.</name><description>&lt;h4>Objective&lt;/h4>This study assessed the anticancer and antimetastatic impact of rivaroxaban-ciprofloxacin mixture and explored its molecular mechanism by examining its ability to target the epithelial-mesenchymal transition (EMT) pathway.&lt;h4>Methods&lt;/h4>Following incubation periods of 24 and 72 hours, HeLa and normal human fibroblast (NHF) cell lines were employed to investigate the anticancer and safety properties of rivaroxaban, ciprofloxacin, rivaroxaban-ciprofloxacin mixture, and carboplatin, with concentrations varying from 0.1 to 1000 µg/ml. The wound healing assay (WHA) of cervical cancer cells was employed to assess the anti-metastatic effects of the mixture at three time points: 0, 12, and 24 hours.. A combination index (CI) and selectivity toxicity index (SI) score were estimat</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Nov</publication><modification>2026-07-16T22:24:56.968Z</modification><creation>2026-07-11T03:11:59.904Z</creation></dates><accession>S-EPMC12948181</accession><cross_references><pubmed>41312948</pubmed><doi>10.31557/APJCP.2025.26.11.4195</doi></cross_references></HashMap>